Quick Answer
INOVIO PHARMACEUTICALS, INC. reported Cash And Cash Equivalents At Carrying Value of $44.27 million for the year ending 2025.
- INOVIO PHARMACEUTICALS, INC. showed a decrease of -32.7% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from INOVIO PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $14.95 million | Q3 2010: $19.39 million | Q1 2011: $37.18 million | Q2 2011: $30.59 million | Q3 2011: $25.30 million | Q1 2012: $11.13 million | Q2 2012: $5.95 million | Q3 2012: $4.59 million | Q1 2013: $20.09 million | Q2 2013: $10.35 million | Q3 2013: $33.07 million | Q1 2014: $98.77 million | Q2 2014: $88.54 million | Q3 2014: $70.67 million | Q1 2015: $26.15 million | Q2 2015: $70.30 million | Q3 2015: $85.47 million | Q1 2016: $41.62 million | Q2 2016: $28.45 million | Q3 2016: $23.25 million | Q1 2017: $22.90 million | Q2 2017: $23.86 million | Q3 2017: $23.28 million | Q1 2018: $37.51 million | Q2 2018: $15.09 million | Q3 2018: $19.40 million | Q1 2019: $20.78 million | Q2 2019: $19.74 million | Q3 2019: $15.85 million | Q1 2020: $158.45 million | Q2 2020: $215.43 million | Q3 2020: $178.70 million | Q1 2021: $83.63 million | Q2 2021: $58.93 million | Q3 2021: $67.94 million | Q1 2022: $59.01 million | Q2 2022: $41.10 million | Q3 2022: $21.99 million | Q1 2023: $28.24 million | Q2 2023: $52.71 million | Q3 2023: $18.80 million | Q1 2024: $19.60 million | Q2 2024: $34.39 million | Q3 2024: $21.69 million | Q1 2025: $39.92 million | Q2 2025: $24.35 million | Q3 2025: $36.57 million.
- Over the full 18 years of available data (2008 to 2025), INOVIO PHARMACEUTICALS, INC.'s Cash And Cash Equivalents At Carrying Value has grown by 213.7%.
- Historical annual values: Fiscal year 2025: $44.27 million | Fiscal year 2024: $65.81 million | Fiscal year 2023: $14.31 million | Fiscal year 2022: $46.33 million | Fiscal year 2021: $71.14 million | Fiscal year 2020: $250.73 million | Fiscal year 2019: $22.20 million | Fiscal year 2018: $23.69 million | Fiscal year 2017: $23.79 million | Fiscal year 2016: $19.14 million | Fiscal year 2015: $57.63 million | Fiscal year 2014: $40.54 million | Fiscal year 2013: $33.72 million | Fiscal year 2012: $5.65 million | Fiscal year 2011: $17.35 million | Fiscal year 2010: $20.00 million | Fiscal year 2009: $30.30 million | Fiscal year 2008: $14.12 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: